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Abstract
Objectives Secretin-stimulated magnetic resonance imag-
ing (s-MRI) is the best validated radiological modality
assessing pancreatic secretion. The purpose of this study
was to compare volume output measures from secretin-
stimulated transabdominal ultrasonography (s-US) to s-
MRI for the diagnosis of exocrine pancreatic failure in
cystic fibrosis (CF).
Methods We performed transabdominal ultrasonography and
MRI before and at timed intervals during 15 minutes after
secretin stimulation in 21 CF patients and 13 healthy controls.
To clearly identify the subjects with reduced exocrine pancre-
atic function, we classified CF patients as pancreas-sufficient
or -insufficient by secretin-stimulated endoscopic short test
and faecal elastase.
Results Pancreas-insufficient CF patients had reduced pancre-
atic secretions compared to pancreas-sufficient subjects based
on both imaging modalities (p < 0.001). Volume output esti-
mates assessed by s-US correlated to that of s-MRI (r = 0.56–
0.62; p < 0.001). Both s-US (AUC: 0.88) and s-MRI (AUC:
0.99) demonstrated good diagnostic accuracy for exocrine
pancreatic failure.
Conclusions Pancreatic volume-output estimated by s-US
corresponds well to exocrine pancreatic function in CF pa-
tients and yields comparable results to that of s-MRI. s-US
provides a simple and feasible tool in the assessment of pan-
creatic secretion.
Key points
• Cystic fibrosis patients with affected pancreas have reduced
pancreatic secretions.
• Secretin-stimulated sonography is a simple and feasible
method to assess pancreatic output.
• Secretin-simulated MRI is a more precise method to assess
pancreatic secretions.
• The sonographic andMRImethods yielded comparable pan-
creatic secretory output estimates.
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Introduction
Cystic fibrosis (CF) is caused by a range of different mutations
of the CF transmembrane receptor CFTR gene [1]. The mech-
anism of pancreatic failure in CF is related to lack of or im-
paired function of the CFTR protein located in the cell mem-
brane of the pancreatic ductal epithelium [2, 3]. End-stage
pancreatic damage in cystic fibrosis is characterised by fatty
infiltration, atrophy and destruction of both the ductal and the
acinar tissue in the pancreas, leading to pancreatic insufficien-
cy [2, 4]. Impaired ductal function is a distinct feature of
pancreatic exocrine insufficiency in CF and also probably
the dominating mechanism in early CF pancreatic failure [5,
6]. Following the advent of new therapeutic approaches using
CFTR modulators in specific genotypes of CF [7], there is an
immediate need for simple clinical tools for valid assessment
of pancreatic ductal function both in adults and children.
Indicators of pancreatic CFTR function are pancreatic
output-volume and pancreatic juice contents of chloride and
bicarbonate [3]. This has been utilised in tube-based tests di-
agnosing pancreas exocrine insufficiency in CF patients [8],
and also recently by our group, measuring bicarbonate con-
centration in duodenal juice from a secretin-stimulated endo-
scopic short test with excellent diagnostic accuracy [9].
Pancreatic fluid flow in response to secretin stimulation in
humans has been studied by MRI (s-MRI) for various pancre-
atic disorders [10]. We evaluated secretin-stimulated duodenal
secretion by s-MRI in CF patients with excellent differentia-
tion between pancreas-sufficient CF patients (CFS) and
pancreas-insufficient CF patients (CFI) [11]. One study was
able to demonstrate the dynamics of postprandial pancreatic
duct secretions by the use of MRI combined with a selective
inversion-recovery pulse [12]. Another recent study evaluated
s-MRI in CF patients focusing on the pancreatic duct dilata-
tion, demonstrating poor diagnostic accuracy [13]. High costs
and technical complexity of the analysis are factors that may
limit the feasibility of s-MRI in a routine clinical setting.
Ultrasonography offers real-time imaging with high tem-
poral and spatial resolution of the pancreas and surrounding
tissue and may be repeated safely many times [14–16]. We
have recently demonstrated that secretin-stimulated
transabdominal ultrasonography (s-US) can detect reduced
pancreatic secretion in various pancreatic diseases, and best
accuracy for exocrine pancreatic failure was achieved for the
method in CF patients [17]. However, s-US has not previously
been compared to other radiological modalities assessing pan-
creatic ductal function.
In this study, we aimed to compare s-US with s-MRI in the
assessment of pancreatic secretory function in CF patients. We
also aimed to compare pancreatic output assessments by both
imaging methods to the endoscopic secretin test.
Methods
Subjects
Adult CF patients treated in an outpatient clinic referral centre
were offered participation in this study. Height and body
weight were recorded and body mass index (BMI) calculated.
Relevant clinical data were retrieved from patient medical
records. For all patients, the CF diagnosis was in accordance
with the diagnostic criteria for CF defined in the CF founda-
tion consensus report [18]. Patients were classified as exocrine
pancreas-sufficient or -insufficient based on bicarbonate con-
centration in duodenal juice and/ or by faecal elastase-1 con-
centration [9, 19]. The examinations were also performed on a
group of healthy controls (n = 13) recruited by advertising and
board notices. In two of the CF patients and two of the healthy
controls, the classification was performed by FE only.
Secretin ultrasound
The subjects fasted overnight. Transabdominal ultrasonogra-
phy was performed in supine position with a transverse or
oblique epigastric probe position. Each examination was per-
formed by a single operator (TE or FE) with >5 years’ expe-
rience in pancreatic sonography. Operators were blinded to
patient diagnosis and pancreas sufficiency status. We used a
GE Logic E9 scanner with a 1–5 MHz CRA probe (GE
Medical Systems and Primary Care Diagnostics, Milwaukee,
WI, USA). The image acquisitions were default abdomen
configuration with frequency of 4.0 MHz, frame rate of 15–
22 f/s and varying depth of scanning.
The descending part of the duodenum was scanned and
images displaying the largest possible fluid-filled area
were stored before and 1, 5, 10 and 15 min after admin-
istration of secretin (Secrelux® 10U/ml. Sanochemia
Diagnostics Deutschland GmbH, Neuss, Germany) intra-
venously, 1 CU/kg, with a maximum dose of 70 CU after
a test dose of 10 CU [20]. The fluid-filled areas were
traced and calculated using incorporated GE software.
The areas measured at each time period were registered,
using peak area for each time series as an estimate for
pancreatic secretory capacity (Fig. 1). We also calculated
area under the curve (AUC) for each time series as an
alternative measure of pancreatic secretory capacity. A
visual evaluation of the traced areas was performed on
the stored images. Examinations in which good quality
tracing of the largest fluid-filled area of the duodenum
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was not achievable in two out of three measures at the 5-,
10- and 15-minute post-secretin time points were
excluded.
Secretin MRI
The method is described in detail elsewhere [11, 21]. s-
MRI was performed after 4 hours of fasting on a 1.5T
Siemens Avanto MR scanner (Siemens Healthcare,
Erlangen, Germany) using a 6-channel body coil and a
24-channel spine matrix coil. Coronal T2-weighted im-
aging (T2 HASTE, breath hold, ET 3500/113, slice
thickness 10 mm, acquisition time 21 seconds) for esti-
mation of secreted pancreatic volume were acquired 10
and 4 minutes prior to intravenous administration of
secretin and after 1, 5, 9 and 13 minutes (Fig. 2).
Secretin was administered over a period of 3 minutes.
Just before secretin, a bolus injection of 20 mg of
hyoscine-butylbromide (Buscopan®) was administered
intravenously to reduce peristalsis. All measurements
of pancreatic volume and calculation of secreted pancre-
atic juice were performed by the same radiologist (GW)
with >5 years’ experience in abdominal imaging. The
images were read and analysed using Agfa Impax 6.4
(Agfa Healthcare, Mortsel, Belgium), NordicICE 2.3.12
(NordicNeuroLab, Bergen Norway) and Vitrea worksta-
tion 6.2 (Vital Images, Minnetonka, MN). Calculation of
intestinal fluid volumes is previously described in detail
[21]. The secreted fluid volumes were calculated as the
difference between estimated intestinal fluid volumes at
the different time points after secretin and the corre-
sponding fluid volume prior to secretin. Peak values in
the time from 5–13 minutes after secretin were used for
calculations. Furthermore, individual AUCs were calcu-
la ted f rom the t ime-sec re t ion curves in each
examination.
Fig. 1 US image from the descending part of the duodenum illustrating
fluid filling before (A, C) and 15minutes after secretin stimulation (B, D).
The upper panels demonstrate a pancreas-insufficient patient, whereas
the lower panels demonstrate a pancreas-sufficient CF patient.
Markings illustrate the duodenal diameter and duodenal area tracing.
Also note the hyperechoic and atrophic appearance of the affected pan-
creas. d, duodenum; g, gallbladder; l, liver; p, pancreas
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Exocrine function testing
Directly after the secretin sonography, in the period be-
tween 30 and 45 minutes after secretin stimulation, we
performed a short endoscopic secretin test with quanti-
fication of aspirated volume and analysis of duodenal
bicarbonate concentration. Details in this method are
described elsewhere [22]. Faecal elastase-1 was mea-
sured by a commercial monoclonal analysis kit
(ScheBo® Biotech, Giessen, Germany). Patients with
peak bicarbonate concentrations ≥ 80 mmol/L or faecal
elastase ≥ 100μg/g were classified as pancreas-sufficient
[19].
Ethical considerations
All subjects were included after written, informed con-
sent. The study was conducted in accordance to the
Helsinki II Declaration [23] and was approved by the
local ethics committee (registration numbers 2010/2857-
7; ClinicalTrials.gov: NCT01446861)
Statistical analysis
Statistics were calculated in SPSS statistics 22 (IBM®
SPSS® Statistics, New York, NY, USA) and SigmaPlot
11, (copyright © 2011 Systat Software Inc., San Jose,
CA, USA). We found low probability of non-normal
distribution of continuous data when tested by the
Shapiro–Wilk test. The results are presented as mean
values and standard deviations (SD), unless stated oth-
erwise. Comparisons between the groups were done by
one way ANOVA and Bonferroni post hoc analysis. We
used a 5% level of statistical significance. AUCs were
calculated by trapezoid rule. Correlation was done as
Pearson’s r. Accuracy data were calculated from receiver
operating characteristic (ROC) curves. Cut-off values for
each of the methods were determined by measured
Fig. 2 T2-weighted MRI images
before (A, C) and 13minutes after
secretin stimulation (B, D) with
hyper-intense fluid signal
segmented in red within defined
region of interest comprising the
duodenum and jejunum
(boundaries marked with red).
The upper panels demonstrate a
pancreas-insufficient patient,
whereas the lower panels
demonstrate a pancreas-sufficient
CF patient. d: duodenum, v:
ventricle, j: jejunum
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values yielding highest sensitivity and specificity ac-
cording to ROC statistics.
Results
Inclusion
Thirty CF patients underwent the sonographic and endoscopic
procedures in the period December 2010 to May 2015. The s-
MRIs were performed concentrated in time at the end of the
inclusion period from 2014 to 2015. The median time interval
between the s-US and the s-MRI was 24 months (range: 6–39
months). Twenty-one CF patients and 13 healthy controls
underwent both s-MRI and s-US. One healthy control was
excluded due to poor visibility for the sonographic measures.
Thus, we included 21 CF patients and 12 healthy controls
having exocrine pancreatic output data for both imaging
methods. According to faecal elastase and duodenal bicarbon-
ate results, 11 CF patients were classified as pancreas-
sufficient (CFS), whereas 10 CF patients were classified as
pancreas-insufficient (CFI). Characteristics of the three groups
are displayed in Table 1. The healthy control group was sig-
nificantly older than the CFS group. There were no significant
differences between the groups with respect to gender or BMI.
Reduced secretin induced fluid output
in pancreas-insufficient cystic fibrosis patients
Secretin-stimulated pancreatic fluid output was assessed by
both ultrasonography and MRI. Post-secretin peak values for
duodenal filling at ultrasonography and intestinal fluid vol-
umes at MRI were both highly significantly lower in the CFI
patients compared to CFS patients and HC (p < 0.001 for both
methods). The corresponding AUC values for both s-US and
s-MRI were also significantly lower in CFI patients compared
to CFS and HC (p < 0.001, Table 2, Fig. 3).
Fluid secretions estimated by duodenal aspirations from the
endoscopic secretin test in the period from 30–45 minutes
after secretin stimulation also suggested severe output failure
in the CFI group compared to the others (p < 0.001).
Interestingly, this parameter also demonstrates a group effect
of reduced secretions in the CFS group compared to the HC
group (p = 0.021). This effect was only confirmed by the US
peak area (p = 0.037).
Correlation and diagnostic accuracy for the detection
of exocrine pancreatic failure
There was significant correlation for peak values and AUCs
between the two imaging modalities (p < 0.001, r = 0.62 and
0.56, respectively; Fig. 4 panel A). Furthermore, the peak
secretory volumes from US and MRI correlated to the aspirat-
ed volumes from endoscopic short test (p < 0.001, r = 0.63 and
0.56, respectively). ROC curves, comparing s-MRI intestinal
volumes, ultrasonography duodenal area peak values and se-
cretory curve AUCs for both modalities demonstrated excel-
lent diagnostic accuracy with corresponding high sensitivities
and specificities for the diagnosis of exocrine insufficiency
when employing suggested cut-off values (Fig. 4 panel B
and Table 3). The difference between the ROC curves was
not significant.
Discussion
In this study, we have compared s-US-assessed pancreatic
secretory capacity to that of s-MRI, showing that the two
imaging methods yield comparable diagnostic performance
indices for the diagnosis of severe exocrine pancreatic insuf-
ficiency in CF. As previously described, both imaging
methods excellently demonstrate reduced duodenal/intestinal
fluid filling after secretin stimulation in CF patients with exo-
crine failure [11, 17]. Furthermore, we found that the
Table 1 Table presenting core
demographic data and data for
pancreatic exocrine function
CFI CFS HC
Number (males) 10 (5) 11 (5) 13 (5)
Age years (SD) 29.3 (13,4) 27.3 (12.5) 40.7 (13.0)*
BMI (SD) 21.6 (2.1) 24.3 (4.1) 23.7 (2.7)
Sweat chloride mmol/l (SD) 111.7 (18.7)* 69.6 (7.6) N/A
Duodenal bicarbonate mEq/L (SD) 10.4 (9.8)# 97.8 (32.1) 116.9 (12.6)
Faecal elastase μg/g (SD) 1.2 (1.8)# 541.4 (156.3) 569.0 (111.0)
Volume EST mL 1.7 (1.5)# 7.6 (3.6) † 11.5 (3.7)
CFI: pancreas-insufficient cystic fibrosis, CFS: pancreas-sufficient cystic fibrosis, HC: healthy controls, SD:
standard deviation. Volume EST: Aspirated volume for endoscopic secretin test. *p < 0.05 compared to CFS,
# p < 0.05 compared to CFS and HC, †p = 0.021 compared to HC.
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pancreatic secretory estimates derived from the two imaging
modalities were highly correlated.
Several studies have demonstrated the feasibility of s-MRI
to estimate pancreatic secretion putatively closely linked to
exocrine pancreatic function [10]. Although a standardisation
of protocols has been suggested, no international consensus is
yet established [10]. We previously demonstrated excellent
diagnostic accuracy of s-MRI in the evaluation of exocrine
pancreatic function CF patients [11], and s-MRI is regarded
as the radiological gold standard for assessing exocrine pan-
creatic function. With the exception of our earlier studies eval-
uating the sonographic functional characteristics of the CF
pancreas [17], there are, to our knowledge, no previous reports
on s-US-assessed pancreatic fluid output in CF patients.
Hence, it seems particularly important to study the s-US-
quantified exocrine pancreatic function measures in relation
to the corresponding measures of exocrine pancreatic function
derived from s-MRI. Interestingly, our study indicates that the
two imaging modalities demonstrate equally well the pro-
found volume output failure in CF patients with exocrine pan-
creatic insufficiency.
The correlation between exocrine insufficiency and re-
duced volume output after secretin stimulation in pancreatic-
insufficient CF patients has previously been demonstrated
through classic invasive exocrine pancreas function tests.
Through these tests, it has been estimated that CF patients
secrete 40% less fluid compared to non-CF controls [2, 3].
Hence, imaging methods estimating secretin-stimulated fluid
output pose promising alternatives to more cumbersome, in-
vasive pancreas function tests in evaluating exocrine pancreas
function in CF patients.
Defining acceptable standards for the evaluation of exo-
crine pancreatic function is challenging. Our strict definition
of exocrine pancreas insufficiency dichotomised the patient
groups. Thus, patients with borderline pancreatic exocrine in-
sufficiency were grouped as CFS. This may explain the slight-
ly lower fluid output observed in the CFS group compared to
the HC group.
In the sonographic method, the presented post-secretin du-
odenal areas are unadjusted for pre-secretin fluid in the duo-
denum. This was chosen, as in the limited area of the upper
duodenum in which the measurements were performed, the
fluid from the pancreas will necessarily pass further distally
during the examination period. In the MRI method, a larger
part of the upper intestine is included in the region of interest
and pre-secretin fluid is contained within the measured vol-
ume during the whole period; thus, we chose to adjust for this
pre-secretin fluid in the MRI method. The different quantifi-
cation approach precludes a direct comparison of absolute
values for pancreatic juice volumes between the two imaging
methods. Nevertheless, the secretory estimates from the two
imaging methods were highly correlated, pinpointing that
both imaging methods capture the same secretory pattern pu-
tatively reflecting the pancreatic exocrine capacity.
Regarding the ultrasonographic method, the quickest and
simplest parameter is the peak traced area. The use of this
simple parameter yields an immediate on-site estimate of the
pancreatic secretion for the patient. However, both instability
and disturbances in the image quality, and the problem of fluid
being lost distally during the observation period may create
some variability in the traced areas. To make the test more
robust to these biases, we calculated AUCs for the time-series.
However, we did not demonstrate any difference between di-
agnostic performances of these two US parameters in our
study.
The data from the secretin MRI demonstrates less variabil-
ity in the secreted volumes. In our earlier study evaluating
MRI [11], we used the secreted volume at the end of the test
as the preferred parameter. This is probably the most feasible
output measure from s-MRI. In the present study, we intended
to make the MRI and the US parameters as comparable as
possible. Thus, we chose to use the peak values for the corre-
sponding time period and the AUC extracted from the time-
secretion curves for both methods.
Finally, the source of intestinal fluid secretions must be
taken into account concerning the effect of differences in
sample volumes between the two methods. In the upper
duodenum, fluid secretions in the post-secretory period
are probably dominated by pancreatic secretions [24].
The presence of the CFTR receptor protein secreting fluid
and bicarbonate from the intestinal wall have been dem-
onstrated, but whether these are secretin-responsive re-
mains to be explored (25, 26). If CFTR in the intestinal
wall responds to secretin, differences between subjects
Table 2 Table presenting
secretory estimates for US and
MRI
CFI CFS HC
MRI intestinal volume mL (SD) 10.7 (7.8)* 79.7 (26.0) 87.0 (23.9)
MRI time-series AUC (SD) 102.8 (78.7)* 660.5 (263.3) 716.8 (228.4)
US fluid-filled duodenal area cm2 (SD) 1.4 (0.6)* 4.9 (2.2)# 6.6 (1.5)
US time-series AUC (SD) 13.5 (6.4)* 49.3 (22.6) 64.9 (19.7)
CFI: pancreas-insufficient cystic fibrosis, CFS: pancreas-sufficient cystic fibrosis, HC: healthy controls, SD:
standard deviation, MRI: magnetic resonance imaging, US: ultrasonography, AUC: area under the curve. *p <
0.001 compared to CFS and HC, #p = 0.037 compared to HC.
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with and without functioning CFTR will probably be in-
creased in the MRI method compared to the ultrasonog-
raphy method, as a larger part of the intestine is included
in the region of interest in the MRI method. The same
effect, however, will reduce the precision in the evalua-
tions of pancreatic function. This may explain why s-US
performs better in differing groups where small differ-
ences in isolated pancreatic secretions are expected.
We acknowledge that in the routine exocrine function
testing the simple and non- invasive faecal elastase is the
test of choice. The place for direct function testing is in
cases where there is doubt about the first-line test. We
have earlier argued about how the use of combined acinar
and ductal direct function testing may aid in the detection
of subjects at risk of developing exocrine pancreatic in-
sufficiency [9].
Fig. 3 US and MRI estimates of intestinal fluid filling at different time
points after secretin stimulation. Error bars represent standard error of the
mean. A: Changes in fluid-filled areas in sections of the descending
duodenum estimated by US. B: Changes in fluid volume of the
duodenum and proximal jejunum estimated by MRI. CFI: pancreas-
insufficient cystic fibrosis, CFS: pancreas-sufficient cystic fibrosis, HC:
healthy control
Fig. 4 Panel A displays the correlation between peak values of intestinal
fluid volumes estimated by MRI and peak values of fluid filled areas in
sections of the descending duodenum estimated by US. There was a
significant positive correlation (r2 = 0.62, p < 0.001). Panel B displays
receiver operating characteristic curves peak intestinal fluid volumes
estimated by MRI and peak fluid-filled areas in the descending
duodenum, estimated by US. The difference between the AUROCs did
not reach significance. MRI: magnetic resonance imaging, US:
ultrasonography, CFI: pancreas-insufficient cystic fibrosis, CFS:
pancreas-sufficient cystic fibrosis, HC: healthy control, AUROC: area
under the receiver operating characteristic curves
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Study limitations
This small study has several limitations. Firstly, a direct com-
parison of ultrasonography and MRI during the same secretin
stimulation was not possible to perform. The examinations are
differentiated in time, thus we cannot claim to present an ideal
back-to-back comparison of the same flow period. In the eval-
uation of CF patients, we argue that this is not a major limita-
tion. Most CF patients develop their complete exocrine failure
in utero or during early childhood [25]. Hence, we would not
expect patients to change from CFS to CFI in the age group of
our patients [26]. Still, there may be differences from day to
day in the pancreatic secretion.
The healthy controls are older than the CF patients. A de-
cline in exocrine secretory capacity with increasing age has
not been reported [27]. Thus, this limitation does not seem
very relevant.
Despite the measures to harmonise the sonographic and
MRI output parameters, additional methodological differ-
ences exist that prevent direct comparability of the values
obtained by the two modalities. Whereas the s-US method is
two-dimensional and based on imaging of the upper duode-
num, the s-MRI gives the opportunity to asses a three-
dimensional volume comprising a larger part of the upper
intestines.
US results may be highly variable due to operator tech-
niques. The attempt of measuring a non-symmetrical, three-
dimensional volume by tracing of a two-dimensional area im-
poses variations, instability in the measures and interobserver
differences. The probe placement in the transverse or oblique
epigastric probe position imaging the pylorus, the head of the
pancreas and the descending duodenum was standardised be-
tween the operators as good as possible. Time was spent to
identify the largest possible fluid-filled area of the descending
duodenum. The traced area was a quite stable parameter after
reaching the first phase of fluid-filling. Interobserver studies
were not performed.
A strict definition of exocrine pancreas insufficiency was
used in the study. Thus, patients with borderline pancreatic
exocrine insufficiency were classified as pancreatic-sufficient.
This design reduces the possibility to evaluate the perfor-
mance of the secretin ultrasound test to define mild or early
insufficiency in CF patients.
Conclusion
In this study, we have demonstrated that exocrine pancreatic
output measures based on s-US and s-MRI are highly corre-
lated in CF patients and that both methods have excellent
diagnostic performance in detecting pancreas exocrine insuf-
ficiency. Due to its three-dimensionality, precision and as-
sumed better reproducibility, s-MRI may seem advantageous
to achieve the most accurate evaluation of pancreatic secretory
function. However, s-US provides an attractive alternative
with its simplicity, safety, low cost and repeatability.
Furthermore, s-US allows immediate estimates of exocrine
pancreatic output and can easily be combined with the endo-
scopic secretin test to obtain complete and direct exocrine
function testing. The fact that US quality was satisfactory in
all but one patient indicates that this technique could be per-
formed reliably in a clinical setting.
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Table 3 Table presenting the
diagnostic performance for the
secretory parameters in detecting
pancreatic insufficiency
Sensitivity Specificity Accuracy Cut-off
MRI Peak volume (mL) 1.0 (0.69–1.0) 1.0 (0.86–1.0) 1.0 (1.0–1.0) 30
AUC 1.0 (0.69–1.0) 1.0 (0.86–1.0) 1.0 (1.0–1.0) 250
US Peak area (cm2) 1.0 (0.69–1.0) 0.96 (0.78–1) 1.0 (0.98–1.0) 2.5
AUC 1.0 (0.69–1.0) 0.91 (0.72–0.99) 0.99 (0.97–1.0) 30
Values in parentheses represent a 95% confidence interval. MRI: magnetic resonance imaging, US: ultrasonog-
raphy, AUC: area under the curve.
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Study subjects or cohorts overlap Some study subjects or cohorts
have been previously reported in the following articles
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et al. Diagnostic Accuracy of a Short Endoscopic Secretin Test in
Patients With Cystic Fibrosis. Pancreas. 2015;44(8):1266–72.
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Diagnostic accuracy of secretin-stimulated ultrasonography of the pan-
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Methodology
• prospective
• case-control study, diagnostic study, observational
• performed at one institution
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